Clinical Trial Update: A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating JMT103 versus zoledronic acid for prevention of bone-related events in patients with bone metastases from solid tumors; currently not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases From Solid Tumors

Drugs mentioned

• JMT103
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors | Phase 3 | Status: NOT_YET_RECRUITING